Photodynamic Therapy System for Patients With Refractory/Unresponsive Solid Tumors
A Multicenter Phase I Safety and Tolerability Study of the Oncolux System for Intratumoral Delivery of Non-Coherent Light for the Photoactivation of LS 11 in Patients With Refractory Solid Tumors
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Arizona
-
Tucson, Arizona, United States, 85723
- University of Arizona, VA Medical Center
-
-
Michigan
-
Detroit, Michigan, United States, 48201
- Detroit Medical Center, Wayne State University
-
-
North Carolina
-
Greenville, North Carolina, United States, 27858
- East Carolina State University, Brody School of Medicine
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19141
- Albert Einstein Medical Center
-
Philadelphia, Pennsylvania, United States, 19104
- University of Pennsylvania School of Medicine
-
-
Washington
-
Seattle, Washington, United States, 98101
- Virginia Mason Medical Center
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Primary Inclusion Criteria:
- Target tumors accessible for percutaneous implantation under CT (and ultrasound if needed) guidance in any superficial location, sarcoma, tumors of oral/oro-pharyngeal cavity, tumors with extensive pelvic involvement, or liver metastasis.
- Patient has failed prior surgery or chemotherapy or radiation therapy and the tumor is refractory.
- Tumor mass is not immediately adjacent to, or directly invading a major vessel or hollow viscus such that tumor necrosis could result in hemorrhage or perforation.
- Patient has not received prior chemotherapy for at least 4 weeks and patient has recovered from toxicity.
- Patient has an ECOG performance status of 0-3 (Karnofsky 30 or higher).
- If patients have received radiotherapy to sites of disease other than the one planned for insertion of the light delivery catheter, then the patient must have no current local or systemic toxicity from the prior radiation.
- Patient has recovered from all previous surgery in the judgment of the Principal Investigator.
- Patient has not been treated with any biologics (excluding hormones) at least 4 weeks prior to the screening and patient has recovered from any toxicity.
- Age 18 or older.
- Minimum life expectancy of 12 weeks.
- Ability to provide informed consent.
All tumors must:
- have a minimum dimension that exceeds 4 x 2.8 cm;
- have a shape and location such that the mid-point on the light delivery catheter will be greater than 2.0 cm from any structure which, if damaged by PDT treatment, would result in pain or injury to the patient.
Exclusion Criteria:
- History of cardiovascular abnormalities, including, myocardial infarction in the last 6 months, arrhythmias, uncontrolled congestive heart failure;
- History of ongoing, significant active medical illness that might create a risk for the patient, in the opinion of the Investigator;
- History of known or suspected porphyria;
- Concomitant use of other drugs known to produce skin photosensitivity;
- Women who are pregnant or lactating;
- Hematopoietic abnormalities from the baseline examination, as evidenced by the following laboratory values (US Units):Hemoglobin <10 g/dL; White blood cell (WBC) count <2500/mm3;Neutrophil count < or = 1500/uL;Platelet count < or = 100,000/mm3;
- Renal or liver function abnormalities from the baseline examination, as evidenced by the following laboratory values(US Units):Serum Creatinine >2.0 mg/dL;Total bilirubin > 2.0 mg/dL; SGOT (AST) > 3x the ULN;SGPT (ALT) > 3x the ULN; GGT> 3x the ULN
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Jay Winship, MD, Sr. Vice President of R & D and Chief Medical Officer
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Study Start
Study Completion
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Digestive System Diseases
- Pathologic Processes
- Neoplasms, Connective and Soft Tissue
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Gastrointestinal Diseases
- Stomatognathic Diseases
- Mouth Diseases
- Colonic Diseases
- Intestinal Diseases
- Intestinal Neoplasms
- Rectal Diseases
- Neoplastic Processes
- Sarcoma
- Head and Neck Neoplasms
- Colorectal Neoplasms
- Neoplasm Metastasis
- Pelvic Neoplasms
- Mouth Neoplasms
- Antineoplastic Agents
- Photosensitizing Agents
- Dermatologic Agents
- Talaporfin
Other Study ID Numbers
Other Study ID Numbers
- LSC-OL001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.